New Merck and Vertex drugs raise standard of care in hepatitis C

@article{Sheridan2011NewMA,
  title={New Merck and Vertex drugs raise standard of care in hepatitis C},
  author={C. Sheridan},
  journal={Nature Biotechnology},
  year={2011},
  volume={29},
  pages={553-554}
}
  • C. Sheridan
  • Published 2011
  • Medicine, Biology
  • Nature Biotechnology
for people on Victrelis-based triple therapy. But the newly approved drugs also have major shortcomings, adding an extra safety and toxicity burden to a treatment that is already difficult to take. Victrelis requires a complicated dosing regimen and also increases the risk of anemia and of neutropenia that can be of lifethreatening severity. Treatment with Vertex’s Incivek, though shorter than its competitor’s, is associated with increased incidence of severe rash, anemia and pruritus. Merck… Expand
Chutes and ladders in hepatitis C nucleoside drug development.
A novel class of highly potent irreversible hepatitis C virus NS5B polymerase inhibitors.
Development of oleanane-type triterpenes as a new class of HCV entry inhibitors.
Potent Hepatitis C Virus NS5A Inhibitors Containing a Benzidine Core.
Discovery of new scaffolds for rational design of HCV NS5B polymerase inhibitors.
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
...
1
2
3
4
5
...